Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

Melanocortin agonists stimulate lipolysis in human adipose tissue explants but not in adipocytes

Møller CL., Pedersen SB., Richelsen B., Richelsen B., Conde-Frieboes KW., Raun K.

Laboratory Study on Systemic / IV, published in BMC Res Notes (2015) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
BMC Res Notes (2015)
Reported sample size
—
Source database
Europe PMC
PMID
26459134
PMCID
PMC4604100
DOI
10.1186/s13104-015-1539-4
Citations
22

Abstract (original English)

Background The central melanocortin system is broadly involved in the regulation of mammalian nutrient utilization. However, the function of melanocortin receptors (MCRs) expressed directly in peripheral metabolic tissues is still unclear. The objective of this study was to investigate the lipolytic capacity of MC1-5R in differentiated adipocytes versus intact white adipose tissue. Results Non-selective MCR agonist α-MSH, MC5R-selective agonist PG-901 and MC4R-selective agonist LY2112688 significantly stimulated lipolysis in intact white adipose tissue, whereas stimulation of MCRs in differentiated adipocytes failed to do so. The lipolytic response of MC5R was decreased in intact human white adipose tissue when co-treating with β-adrenergic antagonist propranolol, suggesting that the effect may be dependent on neuronal innervation via noradrenalin release. Conclusion When developing an anti-obesity therapeutic drug with selective MC4R/MC5R properties, effects on lipolysis in white adipose tissue may be physiologically relevant.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
SynapsesSubcutaneous TissueAdipocytesHumansObesityGlycerolPeptides, CyclicFatty AcidsReceptors, MelanocortinLipolysis

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research